Daewoong introduces Tillots's Asacol in Korea

Daewoong Pharm said it has launched Asacol (mesalazine) in the domestic market, which is the leading drug worldwide for the treatment of Inflammatory Bowel Disease (IBD). It signed a licensing agreement for the exclusive marketing rights for Korea.

The product was developed and first launched in the mid-1980s by Tillotts' UK predecessor. Worldwide sales of Asacol totalled approximately $500 ...